Critical Survey: Atara Biotherapeutics (ATRA) versus The Competition

Atara Biotherapeutics (NASDAQ: ATRA) is one of 286 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its peers? We will compare Atara Biotherapeutics to related businesses based on the strength of its dividends, profitability, risk, analyst recommendations, earnings, institutional ownership and valuation.

Profitability

This table compares Atara Biotherapeutics and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Atara Biotherapeutics N/A -44.82% -41.82%
Atara Biotherapeutics Competitors -5,310.77% -218.27% -39.48%

Valuation & Earnings

This table compares Atara Biotherapeutics and its peers top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Atara Biotherapeutics N/A -$79.04 million -4.32
Atara Biotherapeutics Competitors $284.49 million $34.10 million 84.51

Atara Biotherapeutics’ peers have higher revenue and earnings than Atara Biotherapeutics. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a summary of recent recommendations and price targets for Atara Biotherapeutics and its peers, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Atara Biotherapeutics 1 1 3 0 2.40
Atara Biotherapeutics Competitors 873 3234 11720 233 2.70

Atara Biotherapeutics currently has a consensus price target of $26.75, indicating a potential upside of 78.33%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 46.28%. Given Atara Biotherapeutics’ higher possible upside, equities analysts plainly believe Atara Biotherapeutics is more favorable than its peers.

Risk & Volatility

Atara Biotherapeutics has a beta of 1.26, suggesting that its stock price is 26% more volatile than the S&P 500. Comparatively, Atara Biotherapeutics’ peers have a beta of 5.70, suggesting that their average stock price is 470% more volatile than the S&P 500.

Institutional and Insider Ownership

85.6% of Atara Biotherapeutics shares are owned by institutional investors. Comparatively, 50.3% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 16.2% of Atara Biotherapeutics shares are owned by company insiders. Comparatively, 16.6% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Atara Biotherapeutics peers beat Atara Biotherapeutics on 8 of the 12 factors compared.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells. T-cells are a type of white blood cell. The Company’s product candidate, ATA129, is a third-party derived Epstein-Barr virus CTL for the treatment of Epstein-Barr virus (EBV). ATA188 is in development for the treatment of multiple sclerosis. ATA520, which is a third-party donor derived WT1-CTL, targets cancers expressing the antigen Wilms Tumor 1 (WT1). ATA520 is in Phase I clinical trials. The Company’s T-cell product candidate, ATA230, which is a third-party derived cytomegalovirus-CTL (CMV-CTL), is in Phase II clinical trials for refractory CMV.

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit